Journal
MOVEMENT DISORDERS
Volume 25, Issue 3, Pages S55-S57Publisher
WILEY
DOI: 10.1002/mds.22638
Keywords
Parkinson's disease; MPTP; inflammation
Categories
Funding
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011766, P50NS038370] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG021617] Funding Source: NIH RePORTER
- NIA NIH HHS [R01 AG21617] Funding Source: Medline
- NINDS NIH HHS [P01 NS11766-27A1, P50 NS38370] Funding Source: Medline
Ask authors/readers for more resources
Inflammation is a neuropathological feature of parkinsonian brains and also in experimental models of the disease. It is believed that activated glial cells, which compose the majority of this inflammatory response contribute to the neurodegenerative process through the production of toxic molecules. Therapeutic strategies geared toward reducing inflammation and inhibiting the production of these glial-derived toxic molecules may be a promising neuroprotective strategy for the treatment of Parkinson's disease and related conditions. (C) 2010 Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available